Skip to main content

A Path to the Cure: PRF Becomes a Drug Developer

After 7 years of intense work, PRF and the Progeria Gene Team advance SamPro-2, a gene editing therapy designed to permanently correct the single DNA typo that causes Progeria, into the manufacturing stage.

Sign up for updates